首页 > 市场调查报告书 > 製药

神经疾病

市场调查报告书

商品编码

1378606

抗癫痫药物市场：世代、给药途径、配销通路和地区

Antiepileptic Drugs Market, By Generation, By Route of Administration (Oral, Intravenous, Others ), By Distribution Channel, By Geography

出版日期: 2023年10月16日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2023年全球抗癫痫药物市场规模为70.1亿美元，2030年将达88.1亿美元，预测期内（2023-2030年）年度成长率（年复合成长率）预估为3.3%。

报告范围		报告详情
基准年	2022年	2023年市场规模	70.1亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	3.30%	2030年市场规模预测	88.1亿美元

图 1. 2023 年按世代分類的抗癫痫药物全球市场占有率(%)

抗癫痫药物是为患有癫痫发作的患者开立的。癫痫的主要症状是反覆发作，这是大脑中突然爆发的电活动，暂时影响大脑功能。有些癫痫发作可能会导致您的身体抽搐，而有些癫痫发作可能会导致您失去意识或感到异常的感觉。抗癫痫药物是一类多元化的药物，越来越多地用于治疗癫痫以外的疾病，例如预防偏头痛、神经病变疼痛和双相情感障碍。抗癫痫药物分为三代：第一代、第二代、第三代。每一代都有不同的规格。第一代包括溴化物、苯巴比妥、扑米酮、卡马西平，第二代包括非氨酯、拉莫三嗪、左乙拉西坦等，第三代包括拉科酰胺、醋酸艾斯利卡西平、氯巴札姆等。由于普及上升和这些药物的采用不断增加，预计第三代药物在预测期内的年复合成长率最高。

市场动态

为了将创新新药推向市场，主要企业正在努力采用核准等有机策略，预计这将在预测期内推动全球抗癫痫药物市场的成长。例如，2022 年 3 月，生物製药公司 UCB SA 宣布口服液 CIV FINTEPLA（芬氟拉明）将在美国食品药物管理局上市，用于治疗与肠漏症候群(LGS) 相关的癫痫发作2岁以上。宣布已获得FDA核准。 LGS 是严重的儿童期发病的发育性癫痫性脑病变，其特征是抗药性癫痫发作。

本研究的主要特点

本报告对全球抗癫痫药物市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和復合年度（年复合成长率）。
它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球抗癫痫药物市场的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的资讯。
全球抗癫痫药物市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进入者和财务分析师。
相关人员可以透过用于分析全球抗癫痫药物市场的各种策略矩阵来促进决策。

公司简介
- Novartis AG
- GlaxoSmithKline Plc
- Johnson &Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy's Laboratories Ltd.
- Shanghai Zhimeng Biopharma, Inc.
- Alkem Labs
- SK Biopharmaceuticals
- Eisai Co, Ltd
- IAMA Therapeutics
- Angelini Spa
- Sun Pharmaceutical Industries Ltd.
- UCB SA
- Marinus Pharmaceuticals, Inc.
- Sanofi SA
- Sumitomo Dainippon Pharma Co., Ltd.
- Bausch Health Companies Inc.
- Analysts'Views

第10章章

参考
调查方法

简介目录

Product Code: CMI1701

Global Antiepileptic Drugs Market is estimated to be valued at US$ 7.01 billion in 2023, and is expected to reach US$ 8.81 billion by 2030, exhibiting a Compounded Annual Growth Rate (CAGR) of 3.3% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 7.01 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	3.30%	2030 Value Projection:	US$ 8.81 Bn

Figure 1. Global Antiepileptic Drugs Market Share (%), By Generation, 2023

Anti-epileptic drugs are prescribed for patients who suffer from seizures. The major symptom of epilepsy is repeated seizures, which are sudden bursts of electrical activity in the brain that temporarily affects the functioning of the brain. Some seizures causes the body to jerk and shake, while others cause problems such as loss of awareness or unusual sensations. Anti-epileptic drugs include a diverse class of medications that are increasingly used for conditions apart from epilepsy such as migraine prophylaxis, neuropathic pain, and bipolar disorder. Anti-epileptics are categorized in three generations as first generation, second generation and third generation. Each generation denotes a different specification. The first generation drugs includes Bromide, Phenobarbital, Primidone, and Carbamazepine, second generation drugs include Felbamate, Lamotrigine, Levetiracetam, and others, and third generation drugs includes Lacosamide, Eslicarbazepine Acetate, Clobazam and others. The third generation drugs are anticipated to register the highest CAGR over the foreascted period attributed to rise in the rise in penetration and increasing adoption of these drugs.

Market Dynamics

In order to bring new and innovative drugs to the market, key players are engaged in adopting organic organic strategies such as regulatory approval which is expected to drive the global anti-epileptic drugs market growth over the forecast period. For instance, in March 2022, UCB S.A, a biopharmaceutical company, announced that FINTEPLA (fenfluramine), a oral solution CIV had been approved in theU.S., by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients of age two years and older. LGS is a severe childhood-onset developmental and epileptic encephalopathy characterized by drug-resistant seizures.

Key features of the study:

This report provides an in-depth analysis of the global anti-epileptic drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global anti-epileptic drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Shanghai Zhimeng Biopharma, Inc., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., IAMA Therapeutics, Angelini S.p.a, Sun Pharmaceutical Industries Ltd., UCB S.A, Marinus Pharmaceuticals, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., and Bausch Health Companies Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global anti-epileptic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs market

Antiepileptic Drugs Market Detailed Segmentation:

By Generation:
- First Generation
- Second Generation
- Third Generation
By Route of Administration:
- Oral
- Intravenous
- Others
By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- E-commerce
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles
- Novartis AG
- GlaxoSmithKline Plc
- Johnson & Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy's Laboratories Ltd.
- Shanghai Zhimeng Biopharma, Inc.
- Alkem Labs
- SK Biopharmaceuticals
- Eisai Co., Ltd.
- IAMA Therapeutics
- Angelini S.p.a
- Sun Pharmaceutical Industries Ltd.
- UCB S.A
- Marinus Pharmaceuticals, Inc.
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co., Ltd.
- Bausch Health Companies Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Generation
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Key Developments
Mergers, Acquisitions and Collaborations
Recent Trends
Recent Launches/Approvals
Regulatory Scenario
Reimbursement Scenario
PEST Analysis
Porter's Analysis

4. Global Antiepileptic Drugs Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Antiepileptic Drugs Market, By Generation, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
First Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Second Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Third Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends

6. Global Antiepileptic Drugs Market, By Route of Administration, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends

7. Global Antiepileptic Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Antiepileptic Drugs Market, By Region, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.S.
Canada
Europe
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth ,By Country, 2018 -2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and , Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Novartis AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- GlaxoSmithKline Plc
- Johnson & Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy's Laboratories Ltd.
- Shanghai Zhimeng Biopharma, Inc.
- Alkem Labs
- SK Biopharmaceuticals
- Eisai Co, Ltd
- IAMA Therapeutics
- Angelini S.p.a
- Sun Pharmaceutical Industries Ltd.
- UCB S.A
- Marinus Pharmaceuticals, Inc.
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co., Ltd.
- Bausch Health Companies Inc.
- Analysts' Views